Advances in several fields of cardiovascular (CV) medicine have produced new treatments (e.g. to treat dyslipidaemia) that have proven efficacy in terms of reducing deaths and providing a better quality of life. However, the burden of CV disease (CVD) remains high. Thus, there is a need to search for new treatment targets. Lipoprotein (a) [Lp(a)] has emerged as a potential novel target since there is evidence that it contributes to CVD events. In this narrative review, we present the current evidence of the potential causal relationship between Lp(a) and CVD and discuss the likely magnitude of Lp(a) lowering required to produce a clinical benefit. We also consider current and investigational treatments targeting Lp(a), along with the potential cost of these interventions.

中文翻译：

---

脂蛋白（a）作为心血管疾病预防和相关治疗策略的治疗靶点：重要概述。

心血管 (CV) 医学的几个领域的进展已经产生了新的治疗方法（例如治疗血脂异常），这些治疗方法在减少死亡和提供更好的生活质量方面已被证明有效。然而，心血管疾病（CVD）的负担仍然很高。因此，需要寻找新的治疗目标。脂蛋白 (a) [Lp(a)] 已成为潜在的新靶点，因为有证据表明它会导致 CVD 事件。在这篇叙述性综述中，我们提出了 Lp(a) 与 CVD 之间潜在因果关系的当前证据，并讨论了产生临床益处所需的 Lp(a) 降低的可能幅度。我们还考虑了针对 Lp(a) 的当前和研究性治疗，以及这些干预措施的潜在成本。